|
KMID : 0370220220660020049
|
|
Yakhak Hoeji
2022 Volume.66 No. 2 p.49 ~ p.57
|
|
|
Adverse Events Analysis and Signal Detection of Baricitinib and Tocilizumab, using KIDS-KD: Focusing on the Adverse Events that may Affect COVID-19
|
|
Hur Ji-Young
Shin Ju-Young
|
|
|
Abstract
|
|
|
|
Research shows that some severe COVID-19 patients exhibit an excessive inflammatory response with persistentfever; therefore, the drugs that inhibit one or more components of the pro-inflammatory cascade are administered to prevent theworsening of the condition of such patients. According to current updated COVID-19 guidelines, baricitinib and tocilizumab couldbe administered in COVID-19 patients in certain circumstances. To confirm the safety of these drugs, we analyzed the frequencyof the adverse events and detected signals using KIDS-KD. We defined the signals by proportional reporting ratios (PRR),reporting odds ratios (ROR), and information components (IC). “Respiratory system disease” was frequently reported, with bothbaricitinib (17 cases, 15.0%) and tocilizumab (40 cases, 10.6%). It was also detected as a signal with baricitinib but not withtocilizumab. As the symptoms of COVID-19 are mainly related to the respiratory system, close monitoring is necessary for thesepatients. In relation to the risk of infection with tocilizumab, leucopenia (18 cases, 4.7%) and granulocytopenia (7 cases, 1.8%)were reported, and leucopenia was detected as a signal. With baricitinib, pyelonephritis was detected as a signal; however, noprior research that supports this finding exists. We expect this study to provide basic data on the safety of administeringbaricitinib and tocilizumab for COVID-19 patients in certain circumstances.
|
|
|
KEYWORD
|
|
|
Baricitinib, Tocilizumab, Adverse events, Signal detection, KIDS-KD
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|